A Study of LY2409021 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
LY2409021 is being evaluated for possible treatment in type 2 diabetes. This study is
designed to compare LY2409021 given alone or given in combination with metformin against
placebo the change in hemoglobin A1c after a 24-week treatment period.